Clinical Trials · NCT01392573
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 413
- Start date
- Nov 2011
- Locations
- 86 sites, 7 countries
- Primary endpoint
- Change From Baseline in HbA1c (Glycosylated Haemoglobin)